Simcere Pharmaceutical Group Limited

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:32 29/05/2024 pm IST			5-day change	1st Jan Change
5.78 ^HKD	-0.17%		-0.69%	-14.12%

23/05	Simcere Pharmaceutical Group's Hypnotic Drugs Gets the Nod from Hong Kong Authorities	MT
25/04	Simcere Pharmaceutical’ Profit Down 23% in 2023	MT

Simcere Pharmaceutical Group Limited Announces Resignation of Mr. Zhang Cheng, Effective March 31, 2021

March 31, 2021 at 07:39 pm IST

Simcere Pharmaceutical Group Limited announced that Mr. Zhang Cheng has tendered his resignation as an executive Director and the chief operating officer of the company to the board with effective March 31, 2021 due to his personal career development.

Latest news about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group's Hypnotic Drugs Gets the Nod from Hong Kong Authorities	23/05	MT
Simcere Pharmaceutical’ Profit Down 23% in 2023	25/04	MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	10/04	MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	09/04	CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	21/03	MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	20/03	CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	18/03	MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	15/03	CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	13/03	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	12/03	CI
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA	11/03	MT
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	10/03	CI
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	21/02	CI
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal	20/02	MT
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	19/02	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	19/02	MT
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	18/02	CI
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	18/01	CI
Simcere Pharma Unit's Shareholders Approve Order Collection Agreement	18/01	MT
China Grants Clinical Trial Approval for Simcere Pharmaceutical's Anti-Tumor Medication	15/01	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets	12/01	CI
Simcere Pharmaceutical Group Limited Announces the Phase III Clinical Study of Suvemcitug for Injection in the Treatment of Platinum-Resistant Ovarian Cancer Has Successfully Met the Primary Study Endpoint	04/01	CI
Simcere Pharmaceutical’s Phase Three Cancer Trial Meets Primary Endpoint	04/01	MT
Simcere Pharmaceutical Unit to Buy Production Facility in Jiangsu Province for 42 Million Yuan	02/01	MT

Chart Simcere Pharmaceutical Group Limited

Duration

Period

Chart Simcere Pharmaceutical Group Limited

More charts

Company Profile

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Simcere Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.371 CNY

Average target price

7.984 CNY

Spread / Average Target

+48.65%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SIMCERE PHARMACEUTICAL GROUP LIMITED	-14.12%	1.89B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.43%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.37%	21.27B
SANDOZ GROUP AG	+19.62%	15.23B
CIPLA LIMITED	+19.84%	14.36B
ZYDUS LIFESCIENCES LIMITED	+51.59%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.40%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B

Generic Pharmaceuticals